Kainos Medicine, Inc. (KOSDAQ:284620)

South Korea flag South Korea · Delayed Price · Currency is KRW
1,087.00
-105.00 (-8.81%)
At close: Aug 14, 2025
-8.81%
Market Cap35.97B
Revenue (ttm)820.50M
Net Income (ttm)-11.83B
Shares Out33.09M
EPS (ttm)-421.05
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume883,908
Average Volume481,084
Open1,200.00
Previous Close1,192.00
Day's Range1,069.00 - 1,245.00
52-Week Range960.00 - 6,000.00
Beta1.29
RSI50.94
Earnings Daten/a

About Kainos Medicine

Kainos Medicine, Inc. engages in research and development of various medicines for cancers, brain, and infectious diseases in South Korea and internationally. The company’s product pipeline includes KM-819, which is completed Phase I clinical study for the treatment of Parkinson’s disease; and KM023, a novel non-nucleoside reverse transcriptase inhibitor that is in Phase III clinical study to treat HIV/AIDS. It is developing anticancer agents, including DNA methyltransferase inhibitor; gene target anti-cancer agent; and Ara-C, a cytotoxic anti-... [Read more]

Industry Biological Products, Except Diagnostic Substances
Founded 2007
Country South Korea
Stock Exchange KOSDAQ
Ticker Symbol 284620
Full Company Profile

Financial Performance

In 2024, Kainos Medicine's revenue was 590.37 million, an increase of 120.85% compared to the previous year's 267.31 million. Losses were -12.19 billion, -19.99% less than in 2023.

Financial Statements

News

There is no news available yet.